Key facts
- This page summarizes Adam Hansard's Form 4 filing for Applied Therapeutics, Inc. (APLT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2024, 18:00.
Adam Hansard - 14 Mar 2024 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- APLT
- Reported as of
- 14 Mar 2024
- Net transaction value
- -$263,415
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2024, 18:00:48 UTC
- Prior SEC filing
- 22 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shoshana Shendelman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adam Hansard filed Form 4 for Applied Therapeutics, Inc. (APLT) on 18 Mar 2024.
Change
- Previous filing in this sequence was filed on 22 Dec 2023.
- Current net transaction value: -$263,415.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLT
transaction
Common Stock
Sale
- Transaction value
- $263,415
- Shares
- -48,871
- Change %
- -6.3%
- Price
- $5.39
- Shares after
- 732,919
- Date
- 14 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
Footnote F2
Weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $5.37 to $5.795, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.